Athens Research/Cambio - Excellence in Molecular Biology/25g/FD-001-0101-025

价格
面议
货号:FD-001-0101-025
浏览量:59
品牌:Athens Research
服务
全国联保
正品保证
正规发票
签订合同
商品描述
Peptide Synthesis

Peptide Synthesis : Amino Acids

We offer a high quality and purity full range of the standard 20 FMOC L-amino acids as well as FMOC D-amino acids and other non-natural amino acids for peptide synthesis. Contact us for prices or if you cannot find the amino acid you are looking for via our website or at support@cambio.co.uk.

  • Catalogue
  • Description

Fmoc-D-Ala-OH•H2O

Fmoc-D-Ala-OH•H2O

Matrix Innovation

Catalogue No.DescriptionPack SizePriceQty
  • Change to:
  • €
FD-001-0101-025Fmoc-D-Ala-OH•H2O25gPOAQuantityAdd to Order

Fmoc-D-Ala-OH•H2O

Fmoc-D-Ala-OH•H2O

Matrix Innovation

CAS number

79990-15-1
Catalog numberFD-001-0101
Molecular formulaC18H17NO4•H2O
Molecular weight329.36
AppearanceWhite or off-white powder
Loss on drying≤6.0%
Purity≥98%
Optical rotation 18°± 2° (C=1, DMF)
Enantiomeric purity≤0.5% L-Enantiomer

Fmoc-D-Ala-OH

If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200

Myeloperoxidase Enzyme Immunoassay Kit 髓过氧化物酶 免疫分析试剂盒 Human MPO EIA KIT FEATURES: USE - Measure human MPO in a variety of matrices SAMPLE -Serum, Platelet-Poor Heparin Plasma, Saliva, Urine or Tissue Culture Media SAMPLES / KIT - 40 in duplicate SENSITIVITY - 0.068 ng/mL STABILITY - liquid reagents stable at 4°C QUICK RESULTS - 2.5 HOURS Myeloperoxidase (MPO) is a tetrameric heme-containing protein abundantly produced in neutrophil granulocytes where it plays an important anti-microbial role. During degranulation MPO is released into the extracellular space. There, as part of the neutrophils “respiratory burst”, it produces hypochlorous acid from hydrogen peroxide and Cl–. MPO also uses hydrogen peroxide to oxidize tyrosine to the tyrosyl radical. Both hypochlorous acid and tyrosyl are cytotoxic and when present can kill bacteria and other pathogens. Hereditary deficiency of myeloperoxidase predisposes individuals to immune deficiency. Studies have shown an association between elevated MPO levels and coronary artery disease, and in 2003 it was suggested that MPO may serve as a sensitive predictor of myocardial infarction in patients complaining of chest pain. Since that time the clinical utility of MPO testing in cardiac patients has been solidly established in the literature with well over 100 papers published. In 2010 this clinical application was further refined by additional studies which determined that measuring both MPO and C-reactive protein (CRP) provided more accurate prediction of mortality risk than measuring just CRP alone.